CRISPR gene drives bias inheritance in pests, advancing population-level control while raising questions about resistance and ecological governance.

Opus Genetics targets inherited retinal diseases with one-dose AAV gene augmentations. Read why IRD stock is a Buy.

A local family is sharing their daughter’s story after a nearly two-year search for answers led to a diagnosis of a rare ...

Researchers from the University of Oxford, Nanjing Agricultural University, and Institute of Genetics and Developmental Biology (Chinese Academy of Sciences) have finally identified the master ...

A battle is currently being waged in a federal court in Washington D.C., where two prominent inventors are accusing the USPTO of singling out and stalling their pending patent applications.

Live Science spoke with a bioethicist and sociologist about emerging genomic technologies, including those that enable parents to "score" and "select" IVF embryos.

Researchers at the Weill Institute for Cell and Molecular Biology have uncovered new evidence that two major types of gene-controlling DNA sequences, promoters and enhancers, operate with a shared ...

"Gene editing takes centre stage in FDA’s new rare disease approval pathway" was originally created and published by ...

As the country prepares to celebrate 250 years, a veteran-owned transportation company in the Tri-Cities is building its ...

The FDA accepted a supplemental new drug application to expand the indication for Ryzumvi to include the treatment of ...

FDA PDUFA Goal Date Set for October 17, 2026. RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) ("Opus Genetics” or the "Company) ...

A panel of physicians, biotech leaders and patient advocates took aim at the FDA during a Senate hearing Thursday on how the ...